HQL Pharmaceuticals is a biotech company focused on Drug Discovery, based in Rehovot, Israel. The company was established in 2009 with a goal to exploit commercial opportunities of an extremely powerful new computing platform, called "CSS".
Our mission is to transform Drug Discovery into a computationally driven, highly efficient process, yielding a large diversity of high quality drug candidates, and addressing the toughest scientific challenges. These include but are not limited to: scaffold hopping, antagonizing protein-protein interactions, hitting two targets at the same time, and transforming fragment hits into viable drug candidates.
HQL's revolutionary ChemSpace Scanner (CSS) platform is based on a proprietary digitization of small molecule chemical space, represented in sets of "Super Molecules", and a set of unique algorithms that together enable highly efficient screening of chemical libraries >20 orders of magnitude higher than currently possible, against high resolution drug models. The platform enables designing sets of optimized drug candidates with significantly higher chances of success than current technologies, at substantial cuts in costs and duration, and is designed to tackle extremely tough problems, which pose significant challenges for current technologies.
HQL is committed to the development of novel treatments for unmet medical needs, utilizing the unprecedented technological firepower of its proprietary platform.